Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. (Q46031443)
Jump to navigation
Jump to search
scientific article published in May 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. |
scientific article published in May 2009 |
Statements
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer (English)
966-7; author reply 967